Merck Positions MK-8591 As Backbone For HIV Treatment And Prophylaxis
First-in-class antiviral could be a potential backbone for combo regimens and entry into PrEP. New data releases at IAS highlight potential in both settings.
You may also be interested in...
Merck has already paused other studies testing the potential first-in-class NRTTI and is adding additional monitoring of lymphocyte and CD4+ T-cell assessments.
The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.
Topline results from the Phase III ATLAS-2M study indicate that injections every two months of ViiV/Janssen’s two-drug anti-HIV regimen are non-inferior to a once-monthly injectable regimen.